HPV-16/18 VLP/AS04 vaccine (Cervarix TM)
Sponsors
GlaxoSmithKline
Conditions
Infections, Papillomavirus
Phase 3
Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women
CompletedNCT00344032
Start: 2006-07-28End: 2007-12-04Updated: 2018-07-20
A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
CompletedNCT00485732
Start: 2007-06-11End: 2008-03-30Updated: 2018-07-20